· Elevate neuro-oncology – Today, MR is the gold standard in neuro-oncology imaging. However, opportunities exist for improvement, and new imaging contrast and biomarkers are needed. Philips’ new 3D APT [1] helps address these needs. This contrast-free imaging solution uses unique Philips technology. It effectively supports neuro-oncology clinicians in providing a more confident diagnosis, and features a workflow that leverages optimized and standardized acquisition and visualization techniques.


At RSNA 2017, Philips will officially unveil MR Prodiva 1.5T and its new MR innovations, alongside its full suite of solutions for diagnosis and treatment at booth #6735 in Hall B at McCormick Place on Sunday, November 26 at 11:30 a.m. CT.


For more information about Philips’ presence at RSNA, please visit www.philips.com/rsna, www.philips.com/thenextmrwave, and follow @PhilipsLiveFrom for #RSNA17 live updates.

[1] 510k pending. Not available for sale in the USA or Canada.


About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 73,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Back to HCB News

MRI Homepage